<DOC>
	<DOCNO>NCT00589472</DOCNO>
	<brief_summary>This phase II trial study well androgen deprivation therapy vorinostat follow radical prostatectomy work treat patient prostate cancer spread part body . Androgens cause growth prostate cancer cell . Antihormone therapy , bicalutamide , goserelin acetate , leuprolide acetate , may lessen amount androgen make body . Vorinostat may stop growth tumor cell block enzymes need cell growth . Giving androgen deprivation therapy vorinostat surgery may make tumor small reduce amount normal tissue need remove .</brief_summary>
	<brief_title>Androgen Deprivation Therapy Vorinostat Followed Radical Prostatectomy Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine rate pathologic complete response patient localized prostate cancer treat androgen depletion therapy ( ADT ) oral vorinostat administer minimum 6 week maximum 8 week radical prostatectomy . SECONDARY OBJECTIVES : I . To determine evaluate pre- post-treatment level prostate-specific antigen ( PSA ) , testosterone , dihydrotestosterone ( DHT ) , dehydroepiandrosterone ( DHEA ) , dehydroepiandrosterone-dulfate ( DHEA-S ) blood . II . To determine evaluate pre- post-treatment level testosterone , androstenedione , androstenediol , DHT , DHEA , DHEA-S prostate . III . To determine evaluate gene protein expression analysis include androgen receptor ( AR ) target gene , PSA TMPRSS2 ( transmembrane protease , serine 2 ) , pre-treatment biopsy post-treatment radical prostatectomy . IV . To determine evaluate exploratory gene microarray analysis . V. To determine evaluate safety tolerability ADT combination vorinostat ( SAHA ) assess physical examination , adverse event , laboratory assessment . OUTLINE : Patients receive bicalutamide orally ( PO ) daily ( QD ) 1 month leuprolide acetate intramuscularly ( IM ) goserelin acetate subcutaneously ( SC ) month surgery . Patients also receive vorinostat PO QD begin first day androgen depletion therapy continue 8 week day surgery . Patients undergo open laparoscopic radical prostatectomy . Patients positive surgical margin undergo immediate adjuvant external beam radiotherapy prostatic fossa , base judgment treat physician . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologic documentation prostatic adenocarcinoma 3 biopsy core , least 1 core demonstrates &gt; 30 % involvement tumor ; confirmation localize disease magnetic resonance imaging ( MRI ) endorectal probe available No evidence distant disease : Computed tomography ( CT ) MRI abdomen pelvis Radionuclide bone scan ( plain film MRI confirmation clinically indicate ) Appropriate candidate radical prostatectomy Adequate cardiac function ( evidence cardiac disease evaluate determine appropriateness patient surgical candidate ) Candidates may history deep vein thrombosis , pulmonary embolism , and/or cerebrovascular accident , require concomitant systemic anticoagulation , otherwise deem suitable radical prostatectomy White blood cell ( WBC ) &gt; 3000/uL Platelets &gt; 150,000/uL Creatinine &lt; 2 mg/dL Serum PSA &lt; 100 ng/mL Bilirubin &lt; 1.5 X ULN ( institutional upper limit normal ) Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 2 X ULN Karnofsky performance status &gt; 70 % Willingness undergo pretreatment transrectal ultrasoundguided prostate needle biopsy ( optional ) Willingness use adequate contraceptive method study therapy least 3 month completion therapy Ability understand willingness sign write informed consent document Evidence smallcell , transitionalcell , neuroendocrine pathologic feature Prior hormonal therapy ( e.g . 5alphareductase inhibitor , gonadotropin hormone release analog , steroid , megestrol acetate , nonstudyrelated antiandrogens ) , chemotherapy , herbal medication administer intent treat patient 's malignancy Patients valproic acid ( histonedeacetylase inhibitor ) treat prostate cancer eligible History allergic reaction attribute compound similar chemical biological composition vorinostat Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would compromise compliance study requirement Currently active secondary malignancy ( determined treat physician ) nonmelanoma skin cancer</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>